Simultaneous occurrence of two B-cell malignancies: A case report

August 2014
Oncology Letters;2014, Vol. 8 Issue 2, p908
Academic Journal
Case Study
The present study describes the case of a 75-year-old male with coexisting multiple myeloma and diffuse large B-cell lymphoma. Although the two malignancies are mature B-cell neoplasms, their clinical manifestations are very different and the clinical approaches used to treat these two types of tumor vary. The patient in the present case was diagnosed with the simultaneous existence of two different B-cell tumors and was successfully treated using the DCEP regimen. The simultaneous presentation of two mature B-cell neoplasms, types of hematological malignancy, is very rare, thus the present case is considered to be interesting.


Related Articles

  • Idelalisib approved for three blood cancers. Traynor, Kate // American Journal of Health-System Pharmacy;9/1/2014, Vol. 71 Issue 17, p1430 

    The article reports on the approval by the U.S. Food and Drug Administration (FDA) of idelalisib oral tablets for blood cancer on July 23, 2014. Topics covered include the types of blood cancer indicated in the labeling for the drug, the approval made via the breakthrough therapy program of FDA...

  • Advances in Cellular Therapies for Hematologic Malignancies Highlighted at ASH 2019. Kuznar, Wayne // American Health & Drug Benefits;2020Special issue, Vol. 12, p1 

    The article offers information on American Society of Hematology (ASH) 2019 which featured emergence of cellular immunotherapy for a broad array of hematologic malignancies. Topics discussed include information on history of how T-cells have been engineered to fight Acute Myeloid Leukemia (AML)...

  • The lighter side of myeloma: an easily overlooked diagnosis. Spiller, Robin; Feld, J. J.; Guindi, M.; Heathcote, E. J. // Gut;Oct2005, Vol. 54 Issue 10, p1376 

    Presents case report of a 61 year old man who developed back pain, fatigue, and anaemia. Treatment of the patient; Information that IgG K multiple myeloma was diagnosed and the patient was treated with vincristine, adriamycm, and dexamethasone; Questions related to the diagnosis.

  • Doxorubicin liposomal.  // Reactions Weekly;9/18/2004, Issue 1019, p9 

    Discusses research being done on the side effects of antineoplastic therapy with doxorubicin liposomal in an elderly patient with multiple myeloma. Reference to a study by P. Kiewe and colleagues published in the July to August 2004 issue of "Annals of Pharmacotherapy"; Occurrence of ageusia;...

  • High-dose cyclophosphamide with or without etoposide for mobilization of peripheral blood progenitor cells in patients with multiple myeloma: efficacy and toxicity. Gojo, I.; Guo, C.; Sarkodee-adoo, C.; Meisenberg, B.; Fassas, A.; Rapoport, A.; Cottler-fox, M.; Heyman, M.; Takebe, N.; Tricot, G. // Bone Marrow Transplantation;Jul2004, Vol. 34 Issue 1, p69 

    Summary:The purpose of the study was to examine the yield of CD34+ cells, response rates, and toxicity of high-dose cyclophosphamide with or without etoposide in patients with multiple myeloma. In total, 77 myeloma patients received either cyclophosphamide 4.5?g/m2 (n=28) alone or with etoposide...

  • The Role of Regulatory T Cells and TH17 Cells in Multiple Myeloma. Braga, Walter M. T.; Atanackovic, Djordje; Colleoni, GiseleW. B. // Clinical & Developmental Immunology;2012, p1 

    The development of multiple myeloma (MM) involves a series of genetic alterations and changes in the bone marrow microenvironment, favoring the growth of the tumor and failure of local immune control. Quantitative and functional alterations in CD4+ and CD8+ T cells have been described in MM. The...

  • Single agent dexamethasone for pre-stem cell transplant induction therapy for multiple myeloma. Kumar, S.; Lacy, M. Q.; Dispenzieri, A.; Rajkumar, S. V.; Fonseca, R.; Geyer, S.; Allmer, C.; Witzig, T. E.; Lust, J. A.; Greipp, P. R.; Kyle, R. A.; Litzow, M. R.; Gertz, M. A. // Bone Marrow Transplantation;Sep2004, Vol. 34 Issue 6, p485 

    Summary:Given the survival advantage, high-dose therapy (HDT) remains the standard of care for patients with multiple myeloma eligible for the procedure. For those undergoing HDT, initial therapy aimed at reducing tumor burden is given prior to stem cell harvest. Various regimens, mostly...

  • High-throughput drug screening identifies compounds and molecular strategies for targeting proteasome inhibitor-resistant multiple myeloma. Stessman, H A F; Lulla, A; Xia, T; Mitra, A; Harding, T; Mansoor, A; Myers, C L; Van Ness, B G; Dolloff, N G // Leukemia (08876924);Nov2014, Vol. 28 Issue 11, p2263 

    The article presents a study which develops a high-throughput drug screening (HTS) platform to determine chemical structures that selectively kill or re-sensitize PI-resistant multiple myeloma (MM) cells to proteasome inhibitors (PIs). It states that a cell-based drug screening assay was...

  • A Report of 134 Newly Diagnosed Multiple Myeloma Patients with Renal Impairment. Liu, Aijun; Yang, Guangzhong; Geng, Chuanying; Wang, Huijuan; Li, Lihong; Li, Yanchen; Wu, Yin; Tian, Ying; Leng, Yun; Wang, Guorong; Gao, Wen; Chen, Wenming // Acta Haematologica;Mar2016, Vol. 135 Issue 3, p140 

    To analyze the effects of bortezomib on the prognosis of the newly diagnosed multiple myeloma patients with renal impairment, we assessed the outcomes of 134 multiple myeloma patients with renal impairment (serum creatinine ≥ 178 μmol/l) who were treated at Beijing Chaoyang Hospital....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics